达沙替尼联合化疗治疗初治核心结合因子急性髓系白血病:CALGB 10801
90% 患者达完全缓解,中位随访 45 个月仅 16% 复发,3 年无病生存率和总生存率分别为 75% 和 77%,KIT 突变患者预后与野生型相当。
要点
- 达沙替尼联合化疗在初治 CBF-AML 中未出现意外或剂量限制性毒性。
- KIT 突变患者 3 年无病生存率和总生存率与野生型相当。
核心结论
- 达沙替尼联合化疗在初治 CBF-AML 中安全可行,完全缓解率高、复发率低,KIT 突变患者预后与野生型相当。
主要发现
- 3 年无病生存率和总生存率分别为 75% 和 77%。
- 年轻患者(<60 岁)3 年无病生存率和总生存率分别为 79% 和 85%,老年患者(≥60 岁)分别为 60% 和 51%。
- KIT 突变患者 3 年无病生存率和总生存率分别为 67% 和 73%,野生型分别为 75% 和 76%。
临床怎么用
- 初治 CBF-AML 可考虑在化疗基础上联合达沙替尼,需关注 KIT 突变状态但不应据此排除联合治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) with either t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22) is referred to as core binding factor (CBF) AML. Although categorized as favorable risk, long-term survival for these patients is only ∼50% to 60%. Mutated (mut) or overexpressed KIT, a gene encoding a receptor tyrosine kinase, has been found almost exclusively in CBF AML and may increase the risk of disease relapse. We tested the safety and clinical activity of dasatinib, a multi-kinase inhibitor, in combination with chemotherapy. Sixty-one adult patients with AML and CBF fusion transcripts (RUNX1/RUNX1T1 or CBFB/MYH11) were enrolled on Cancer and Leukemia Group B (CALGB) 10801. Patients received cytarabine/daunorubicin induction on days 1 to 7 and oral dasatinib 100 mg/d on days 8 to 21. Upon achieving complete remission, patients received consolidation with high-dose cytarabine followed by dasatinib 100 mg/d on days 6 to 26 for 4 courses, followed by dasatinib 100 mg/d for 12 months. Fifteen (25%) patients were older (aged ≥60 years); 67% were CBFB/MYH11-positive, and 19% harbored KITmut. There were no unexpected or dose-limiting toxicities. Fifty-five (90%) patients achieved complete remission. With a median follow-up of 45 months, only 16% have relapsed. The 3-year disease-free survival and overall survival rates were 75% and 77% (79% and 85% for younger patients [aged <60 years], and 60% and 51% for older patients). Patients with KITmut had comparable outcome to those with wild-type KIT (3-year rates: disease-free survival, 67% vs 75%; overall survival, 73% vs 76%), thereby raising the question of whether dasatinib may overcome the negative impact of these genetic lesions. CALGB 10801 was registered at www.clinicaltrials.gov as #NCT01238211.
引用
- Marcucci G, Geyer S, Laumann K, et al. Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Adv. 2020. PMID: 32092139. doi:10.1182/bloodadvances.2019000492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。